EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+0.43%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$992M
AUM Growth
+$992M
(+12%)
Cap. Flow
+$36.7M
Cap. Flow
% of AUM
3.7%
Top 10 Holdings %
Top 10 Hldgs %
53.33%
Holding
74
New
18
Increased
22
Reduced
22
Closed
6
Top Buys
| 1 |
Vaxcyte
PCVX
|
$24.1M |
| 2 |
Revvity
RVTY
|
$20.4M |
| 3 |
UnitedHealth
UNH
|
$18.9M |
| 4 |
Illumina
ILMN
|
$18.9M |
| 5 |
Avantor
AVTR
|
$18.9M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$52.4M |
| 2 |
HealthEquity
HQY
|
$20.5M |
| 3 |
HCA Healthcare
HCA
|
$20.1M |
| 4 |
Neurocrine Biosciences
NBIX
|
$18.5M |
| 5 |
Natera
NTRA
|
$16.4M |
Sector Composition
| 1 | Healthcare | 99.94% |
| 2 | Financials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$23.1B
| $135M | 12.37% | 796,375 -97,346 | -11% | -$16.4M |
|
2
GSK
GSK
$79.9B
| $86.1M | 7.92% | 2,242,388 -380,858 | -15% | -$14.6M |
|
3
Vera Therapeutics
VERA
$1.38B
| $56.1M | 5.16% | 2,383,055 +484,251 | +26% | +$11.4M |
|
|
4
Revvity
RVTY
$10.5B
| $49.4M | 4.54% | 510,330 +211,243 | +71% | +$20.4M |
|
|
5
Vaxcyte
PCVX
$4B
| $42.2M | 3.88% | 1,298,514 +741,444 | +133% | +$24.1M |
|
|
6
HCA Healthcare
HCA
$94.5B
| $38.3M | 3.52% | 99,983 -52,519 | -34% | -$20.1M |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $38.1M | 3.5% | 4,065,355 -146,915 | -3% | -$1.38M |
|
8
Bruker
BRKR
$5.16B
| $34.6M | 3.18% | 839,284 +340,077 | +68% | +$14M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $26.6M | 2.45% | 1,902,539 +524,865 | +38% | +$7.34M |
|
10
Ionis Pharmaceuticals
IONS
$6.79B
| $23.3M | 2.14% | 588,900 +71,879 | +14% | +$2.84M |
|
11
Centene
CNC
$14.3B
| $21.6M | 1.99% | 398,726 +58,387 | +17% | +$3.17M |
|
12
Inspire Medical Systems
INSP
$2.77B
| $21.3M | 1.96% | 164,473 -21,952 | -12% | -$2.85M |
|
13
Community Health Systems
CYH
$387M
| $20.9M | 1.92% | 6,144,384 -2,313,636 | -27% | -$7.87M |
|
|
14
Avantor
AVTR
$9.18B
| $20.5M | 1.89% | 1,526,164 +1,403,341 | +1,143% | +$18.9M |
|
15
Bio-Techne
TECH
$8.5B
| $20.3M | 1.87% | 394,139 +114,022 | +41% | +$5.87M |
|
16
Travere Therapeutics
TVTX
$1.56B
| $19.5M | 1.79% | 1,315,033 +498,779 | +61% | +$7.38M |
|
17
ZimVie
ZIMV
$532M
| $19.4M | 1.79% | 2,079,380 | – | – |
|
|
18
UnitedHealth
UNH
$281B
| $18.9M | 1.74% | +60,736 | New | +$18.9M |
|
|
19
Illumina
ILMN
$15.8B
| $18.9M | 1.74% | +198,584 | New | +$18.9M |
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| $17.6M | 1.62% | 1,052,881 -357,884 | -25% | -$6M |
|
21
Celldex Therapeutics
CLDX
$1.47B
| $17.1M | 1.57% | 838,736 +142,237 | +20% | +$2.89M |
|
22
United Therapeutics
UTHR
$13.8B
| $17.1M | 1.57% | 59,366 +1,877 | +3% | +$539K |
|
|
23
HealthEquity
HQY
$7.72B
| $16.3M | 1.5% | 155,868 -196,108 | -56% | -$20.5M |
|
24
IQVIA
IQV
$32.4B
| $15.4M | 1.41% | +97,604 | New | +$15.4M |
|
25
Protagonist Therapeutics
PTGX
$3.67B
| $15.3M | 1.41% | 277,316 -269,800 | -49% | -$14.9M |
|